CEO and Co-founder Daniel Oliver share how he and his co-founder started the company and their vision for treating age-related conditions.

BIO’s first annual report on diversity in the workplace found room for improvement, as biotech workforces – especially at the executive level – were found to not represent the U.S. population. The report was based on a survey of nearly 100 companies in late spring 2019.

The rules are still more restrictive than the European Medicines Agency’s, which allow national governments to determine interchangeability. The FDA would require additional testing to demonstrate products can be freely substituted like generic pharmaceuticals.

The biotech century has arrived, and it’s consequently now more important than ever for us to highlight our coverage of biopharma.

The report, by PitchBook, shows figures consistent with a similar report earlier this month by Silicon Valley Bank, which forecast more M&A deals this year.

The acquisition brings together two of the largest drugmakers in the country, both of which are major players in biopharma, particularly oncology.

Although blockchain faces regulatory hurdles and skepticism, its potential as a shared, yet secure ledger system to improve the pharmaceutical supply chain integrity and clinical trials is making it attractive for experimentation and investment by drugmakers.

The company’s life sciences track-and-trace network reaches drugmakers, pharmacies and others, with a customer base of more than 930 companies.

In many ways, the biotech field is the healthcare equivalent to the Millennial generation.